ARCHIVES

Pfizer’s Inlyta Gives FDA a Teaching Moment: Not All PFS Advantages Are Created Equal

This article is from The Cancer Letter archive.

Vol. 37 No. 46 | December 16, 2011

Download PDF Visit The Full Archive

Related Articles

ASCO’s Lichter Says. Dingell, Stupak Urge FDA To “Act With Due Haste To Avoid Endangering Patients” Steered To ESAs.

March 7, 2008

Dexamethasone Improved Survival Of Leukemia

November 26, 2004

DCPTC Proceeding With Plans For Intramural Lab

January 30, 1987

Anti-Nausea Drug Successful In Phase III Trial in Highly Emetogenic Chemotherapy

May 30, 2014

Text Of Working Group’s Recommendations

May 19, 1995

NIH Updates Policy On Large Grants

May 10, 1996